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Abstract: Traditional treatment of amblyopia, although still in use and of great value, has 
recently been challenged by data from studies relative to efﬁ  cacy of different modalities and 
regimens of therapy. LogMAR-based acuity charts should be used, whenever possible, for 
diagnosis and monitoring. Refractive errors of certain magnitude should be prescribed, and 
correction worn for at least 4 months before occlusion or penalization are used. Occlusion has 
a linear dose-response effect (1 logMAR line gain per 120 hours of patching), and outcomes 
of 2 hour/day dosage are similar to more extended therapy, at least in moderate amblyopia, but 
increasing dosage beyond hastens the response. Pharmacologic, optical, or combined penalization 
is useful as an alternative or maintaining therapy, and is presumably of particular efﬁ  cacy in 
anisometropic amblyopia. At least in moderate amblyopia, atropine penalization is as effective 
as patching in terms of visual acuity improvement and stereoacuity outcome.
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Deﬁ  nition, classiﬁ  cation, and epidemiology
Traditionally, amblyopia has been deﬁ  ned as a “decrease of visual acuity for which 
no causes can be detected by the physical examination of the eye, caused by vision 
deprivation or abnormal binocular interaction” (Von Noorden 1996). Amblyopia is 
the most common cause of monocular visual impairment in both children, and young 
to middle-aged adults, affecting 2%–5% of the general population. The condition is 
characterized by causing altered visual function (not only affecting recognition visual 
acuity), eg, decreased Vernier acuity, and impaired contrast sensitivity, particularly to 
detect high spatial frequency stimuli. It usually affects one eye, but not invariably.
The ﬁ  rst cause of amblyopia in frequency is strabismus (about 50%), usually 
esotropia in infancy or early childhood. The second cause is anisometropia 
(approx. 17%), followed by a combination of strabismus and anisometropia (about 
30%), and ﬁ  nally the least frequent cause is visual deprivation (3%) although this 
one may result in severe amblyopia (Hillis et al 1983).
Binocularity and stereopsis are most likely to be affected in strabismic amblyopia. 
Bilateral refractive error may cause amblyopia (refractive amblyopia, of which 
anisometropic amblyopia is the most frequent case). Isoametropic amblyopia occurs 
usually in children with hyperopia greater than 4.50 diopters (Klimek et al 2004). 
Myopic anisometropia rarely causes amblyopia until the anisometropia is 2.00 
diopters, although hyperopic anisometropia may occur with as little as a 1.00-diopter 
difference between the eyes (Weakley 2001). Anisometropia of 1.50 diopters may 
cause amblyopia (Weakley 2001).
Previous research has demonstrated that the developing visual system is highly 
sensitive to deprivation (Huebel and Wiesel 1970). Any factor that leads to deprivation 
during the visual sensitive period, ending at approximately 6 to 7 years, may cause 
amblyopia (Von Noorden and Crawford 1979).Clinical Ophthalmology 2007:1(4) 404
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This review will focus on unilateral amblyopia caused 
by strabismus, anisometropia, or both.
Necessity of amblyopia therapy
Authorities have questioned whether amblyopia should 
be treated, due to a lack of proven beneﬁ  t, and because it 
appeared not to be a functional limiting factor and therapy 
with patching was thought to be psychologically distress-
ing (Snowdon and Stewart-Brown 1997). Some studies that 
provide data about natural history of amblyopia suggest 
that mild degrees of amblyopia may resolve spontaneously 
(Snowdon and Stewart-Brown 1997). Other groups defend 
active therapy as an essential way to improve visual acuity 
in amblyopic eyes (Simons and Preslan 1999; Cleary 2000). 
There are few data about the degree of disability associated 
with unilateral amblyopia and the degree of disability 
associated with reduced stereoacuity. Chua and Mitchell 
(2004), found that amblyopia in people 49 years or older 
did not affect lifetime occupational class, but fewer people 
completed higher university degrees. Amblyopes are at 
risk of being limited if they lose vision in their better eye. 
A study found a lifetime risk of visual impairment ranging 
from “socially signiﬁ  cant” to severe in the better eye of 
amblyopes to be 0.03% by age 15 years, 0.6% by 64 years, 
and 3.3% by 95 years (Rahi et al 2002). Injury was the most 
important cause of visual loss in the two younger groups, 
and age-related macular degeneration the primary cause in 
those older than 65 years. In a previous study, Tommila and 
Tarkkanen (1981) found that individuals with amblyopia 
were at increased risk of blindness. The occurrence of visual 
loss during the period tested in healthy eyes was 1.75 per 
1000 people, while the blindness rate was 0.11 per 1000 in 
children and 0.66 per 1000 in adults. In more than 50%, the 
cause of visual loss in healthy eye was traumatic.
In a recent study, bilateral visual impairment (bilateral 
visual acuity 0.5) risk is calculated in amblyopes and 
compared with nonamblyopes (Van Leeuwen et al 2007). 
Amblyopia nearly doubles the lifetime risk of bilateral visual 
impairment.
Worse natural history when left untreated and prevention 
of future visual disability are good reasons for treatment of 
amblyopia in children.
Cost-effectiveness of amblyopia 
therapy
Certain interventions in ophthalmology, such as laser 
treatment for retinopathy of prematurity (Brown et al 1999) 
and choroidal neovascularization (Brown et al 2000), have 
been shown to be very cost-effective. Amblyopia therapy 
is cost-effective to a large degree because the visual acuity 
beneﬁ  t derived is acquired at a very young age, similar to 
that of retinopathy of premature interventions (Membreno 
et al 2002).
Cost-utility studies incorporate the value of improvement 
in quality of life conferred by an intervention with the costs 
associated with it. The term QALYs (quality adjusted life 
years) is used, which considers both the duration of health 
states and their impact on health-related quality of life. It has 
been suggested that interventions with a $/QALY gained of 
50,000$ are highly cost-effective (Kallmes and Kallmes 
1997; Smith and Roberts 2000). Amblyopia treatment 
resulted in a $/QALY gained range from $2053 to $2509 
in a recent publication (Membreno et al 2002). Another 
publication found similar results on amblyopia treatment, 
ie, 2369 $/QALY (König and Barry 2004).
If only bilateral visual impairment, but not unilateral, was 
associated with a loss in utility, treatment would not be likely 
considered cost-effective (König and Barry 2004).
Diagnosing and monitoring 
amblyopia
We diagnose unilateral amblyopia when a patient has reduced 
visual acuity in the presence of an amblyogenic factor, once 
we have prescribed optimum refractive correction and no 
other cause explains the impaired visual acuity. Ideally, 
therefore, measurement of visual acuity is the ﬁ  rst step in 
the diagnosis of amblyopia.
In children younger than 3 years, it is difﬁ  cult to make 
an accurate diagnosis of amblyopia. In young children and 
disabled adults, visual acuity can be estimated by preferential 
looking techniques (Teller acuity cards; Cardiff acuity test) 
(Kay 1983; Wright et al 1986; Hazell 1995; Getz et al 1996; 
Rydberg et al 1999; Wallace 2005), ﬁ  xation preference tests, 
or picture charts. Preferential looking procedures usually 
underestimate amblyopia, especially strabismic amblyopia 
(Mayer et al 1984; Rydberg et al 1999; Woodhouse et al 
2007). These visual acuity tests are not generally considered 
suitable for the diagnosis of amblyopia (Rydberg and Ericson 
1998). Picture charts (like Kay charts and Lea symbols) 
have been used in children aged 2–4 years. Similarly, they 
seem to underestimate amblyopia (Allen 1957). However, 
Lea symbols (Hyvärinen et al 1980), in which four pictures 
were designed to have similar shapes and contours like the 
Landolt C, have several advantages. Lea symbols show a 
higher applicability compared with Landolt C, which is the 
standard visual acuity optotype, in young children (Becker Clinical Ophthalmology 2007:1(4) 405
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et al 2002). Comparing both optotypes, there is only a little 
difference between Lea symbol acuity and the Landolt C 
acuity, even in strabismic amblyopia (Gräf et al 2000). 
Using Lea symbols test, visual acuity may surpass Landolt 
C acuity by 1.2 or 1.9 lines for single or crowded optotypes, 
in normal eyes. This difference decreases with increasing age 
because of cooperation, visual and intellectual development. 
In adults, this difference may be only 0.5 lines (Becker et al 
2002). In both amblyopes and healthy eyes, visual acuity 
measurements are better on HOTV testing compared with 
Lea symbols testing. There is no overestimation in visual 
acuity by Lea symbols when compared with HOTV testing. 
(Ruttum and Dahlgren 2006).
The Amblyopia Treatment Study (ATS) found that 
amblyopic eye visual acuity improved even when it did not 
become the preferred eye (PEDIG 2003a). The difﬁ  culty in 
evaluating amblyopia via ﬁ  xation-based measures is illus-
trated by a study that compared amblyopia treatment duration 
in two groups of patients. In the younger group, treatment 
was discontinued on the basis of equal ﬁ  xation behaviour 
or preferential looking, and in the older group on the basis 
of Snellen chart or Allen pictures (Oster et al 1990). The 
younger group and the Allen-picture-tested segment of the 
older group were more likely to have had uncorrected mea-
sured amblyopia and/or undetected residual amblyopia at the 
end of treatment, than the Snellen-chart-tested older group. 
The younger group was found to need signiﬁ  cantly less patch-
ing to reach equal vision by their eye movement criteria than 
the amount of patching needed by the older group to reach 
their chart-based criteria. But as the younger group became 
older and more accurately measurable, it turned out to require 
maintenance patching therapy, whereas the older group did 
not. This can be explained by underestimation of the depth 
of amblyopia and/or overestimation of the effectiveness of 
treatment by the ﬁ  xation measure, because ﬁ  xation preference 
testing is usually associated with overdiagnosis of amblyopia 
(Atilla et al 2001).
Sometimes children aged 3 years or older can perform 
complete optotype visual acuity testing, but many times it is 
not possible until 4 or 5 years of age, allowing quantiﬁ  cation 
of visual acuity on a Snellen chart (Landolt C, E test, 
letters – like the STYCAR test using HOTVLXAUC 
optotypes, Browder and Levy, 1974 –, numbers) or preferably 
logMAR scale. Landolt C optotypes are more difﬁ  cult to 
see than letter optotypes of the same height. This difference 
occurs at normal and low levels of visual acuity (Rassow and 
Wang 1999). When using Snellen E test, we should assume 
that a small overestimation in visual acuity is produced when 
compared with Landolt C. This small difference appears in 
people with poor and good visual acuity (Becker and Gräf 
2006). Because of this, optotypes should be calibrated against 
the standard Landolt C optotype in order to compare visual 
acuity scores. The height of the typeface of letters (C, D, E, K, 
N, P, U, Z) should be 5% less than the Landolt ring diameter 
in order to achieve the same legibility. Similarly, when 
using shape optotypes like Snellen E and KOLT test, that 
should be 15% smaller than the diameter of the ring to obtain 
comparable visual acuity scores (Grimm et al 1994).
Examples of logMAR-based tests are HOTV optotypes 
used in the ATS visual acuity protocol (Holmes et al 2001), 
the Glasgow cards using XVOHUY optotypes (Mc Graw 
and Winn 1993), and Early Treatment Diabetic Retinopathy 
Study (ETDRS) test (Ferris et al 1982; Atkinson and 
Braddick 1983; Beck et al 2003). Use of a non-logMAR 
scale, such as the classic Snellen chart, introduces errors due 
to the nonequal increments between one level and the next. 
LogMAR tests conform to a regular geometric progression, 
have equal numbers of letters on each line, and use letters of 
near equal legibility and so permit interpolated scores.
The Glasgow Visual Acuity Test consists of a single 
chart line, with surround contours (Morad et al 1999). 
Addition of the surround contour interaction bars is signiﬁ  -
cant because there is evidence that a nonsurrounded single 
line produces indicated visual acuity half-way between the 
level of full chart visual acuity and single-optotype visual 
acuity. Although this test has demonstrated more sensitivity 
to detect amblyopia than single optotype test, it has not yet 
been validated for amblyopes against other tests (Mc Graw 
et al 2000).
The chart version of the HOTV test has been extensively 
used in preschool vision screening and in some clinical testing 
(Harvey et al 1999; Kvarnström et al 2001). Although it has 
demonstrated to have high testability in that age range, it has 
not been validated in amblyopes (Hered 1997). A simpler 
alternative is a single-letter HOTV optotype with surround 
bars (used by PEDIG), which has already been validated and 
demonstrated to be testable in most children as young as 3 to 
3.5 years (Holmes et al 2001; Moke et al 2001).
Most visual acuity tests for amblyopia use isolated letters 
surrounded by crowding bars or letters which are presented in a 
line of 4 or 5 letters. Visual acuity tests with single uncrowded 
letters seem to be insensitive to amblyopia (Rydberg et al 1999). 
Crowding (a reduction of visual acuity when optotypes are pre-
sented in a line or surrounded by bars) seems to be a feature of 
the developing visual system, which persists in amblyopia and 
cerebral visual impairment (Atkinson and Braddick 1983).Clinical Ophthalmology 2007:1(4) 406
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In the MOTAS (Monitored Occlusion Treatment of 
Amblyopia Study), visual acuity is tested using distance 
log-based charts (Stewart et al 2004a). Three logMAR visual 
acuity charts are employed depending on subject age and 
ability: ETDRS , crowded, and single logMAR charts. The 
visual acuity test used at the ﬁ  rst study session was used 
throughout the study period.
Amblyopia treatment
All treatments for amblyopia are based on forcing the use of 
the amblyopic eye. In general, treatment consists of limit-
ing the use (visual input) of the sound eye by patching or 
penalization, after any necessary refractive correction has 
been prescribed (and provided that any obstacle to vision 
has been removed).
Although not all types of amblyopia need the same 
treatment modality, there are general guidelines for treat-
ment. In deprivation amblyopia (eg, cataract or ptosis), 
ﬁ  rst we need to correct the cause of visual impairment, and 
then the disorder should be treated similarly to other types 
of amblyopia. In anisometropic amblyopia, the ﬁ  rst step is 
correction of refractive errors with spectacles or contact 
lenses (frequently followed by occlusion or penalization). 
Strabismic amblyopia is usually recommended to be treated 
(with initial prescription of refractive correction included) 
before surgery for strabismus, although the timing of surgery 
relative to amblyopia therapy is controversial (Lam et al 
1993). Strabismus surgery in these cases is not a therapeutic 
procedure for amblyopia.
In 1997, the Pediatric Eye Disease Investigator Group 
(PEDIG) was formed to conduct research on eye disorders in 
children. The power of this group lies in its ability to conduct 
multiple trials with simple protocols. Patients are enrolled 
at multiple clinical sites, both university- and community-
based. Clinical trials are performed with standardized visual 
acuity testing in a prospective, randomized mode.
Refractive treatment
Prescribing the optimum refractive correction is the ﬁ  rst step 
in the treatment of amblyopia. It provides a clear image to 
the fovea of the amblyopic eye, perhaps for the ﬁ  rst time. 
With the optimum refractive correction in place, any residual 
visual deﬁ  cit is, by deﬁ  nition, due to amblyopia.
Not all degrees of refractive error are thought to induce 
amblyopia. Table 1 summarizes the degrees of refractive 
error that may result in amblyopia. In some cases, refractive 
error should be corrected to obtain the true best-corrected 
visual acuity, especially in cases of myopia.
Recently, some researchers have investigated the role 
of refractive correction alone in the treatment of amblyopia 
(Moseley et al 1998, 2002). A prospective, multicenter, 
noncomparative research demonstrated anisometropic 
amblyopia improvement and even resolution in children 
aged 3 to 7 years with refractive correction alone. Treatment 
outcome was not related to age, but was related to better 
baseline visual acuity and lesser amounts of anisometropia 
(Cotter et al 2006). Other prospective, noncomparative studies 
measured the improvement in anisometropic amblyopia with 
spectacle correction alone in children from 3 to 7 years. These 
previously nontreated anisometropic patients obtained a four 
line improvement in visual acuity and amblyopia resolved in 
nearly half of them. Generally, the improvement occurred in 
the ﬁ  rst two months. After four months with no improvement 
in visual acuity, occlusion or atropine penalization may be 
considered (Chen et al 2007).
Refractive surgery is a therapeutic option in certain cases. 
Eleven anisometropic children underwent photorefractive 
keratectomy with excimer laser. The authors of the study 
concluded that photorefractive keratectomy for severe 
anisometropic amblyopia in children resulted in long-term 
stable reduction in refractive error and improvement in visual 
acuity and stereopsis (Paysse et al 2006).
Another group studied the results in anisometropic 
amblyopia treatment with laser subepithelial keratomileusis 
(LASEK) and photorefractive keratectomy (PRK) in myo-
pic children aged 4 to 16 years. Visual acuity improved 
postoperatively in 97% (by 2 or more optotype lines in 60%) 
Table 1 Degrees of refractive error that may result in amblyopia 
or should be treated with glasses
  Age 0–1  Age 1–2  Age 2–3  PEDIG**
 year* years* years*
Isometropia      
Myopia  –4.00  –4.00  –3.00  –3.00
Hyperopia¹  +6.00  +5.00  +4.50  +3.00
Hyperopia with  +2.00  +2.00  +1.50 
esotropia²
Astigmatism³  3  2.50  2.00 
Anisometropia      
Myopia  –2.50  –2.50  –2.00  –1.00
Hyperopia  +2.50  +2.00  +1.50  +1.00
Astigmatism³  2.50  2.00  2.00  1.50
Notes: *Prescribing guidelines from the American Academy of Ophthalmology 
for refractive error correction; ¹Reduce the amount of refractive error by up to 
+2.00 D, and if this is ≥ +7.00 D, reduce up to +3.00 D; ²Give the full cycloplegic 
refraction. If ≥ +3.00 D, reduce it by +0.50 D; ³When astigmatism is oblique, it must 
be corrected if >1.00 D; **Minimum amount of refractive error that should be ﬁ  rst 
treated with spectacles in recent trials by the Pediatric Eye Disease Investigator 
Group (2002).Clinical Ophthalmology 2007:1(4) 407
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during a mean follow-up 29 months. Recurrence of myopia 
was common, so they concluded that further study is need 
to determine long-term stability and safety (Tychsen et al 
2005).
Not only anisometropic amblyopia but also strabismic 
amblyopia improves with refractive correction alone. 
A recent study reported visual acuity improvement in 
previously untreated strabismic amblyopia in 75% of patients 
with no other treatment. All had constant strabismus and 
were diagnosed of anisometropia of 0.75 diopters (D) or 
less in spherical equivalent or 1.25 D or less in astigmatism. 
Mean change from baseline to maximum improvement was 
2.2 ± 1.8 lines (Cotter et al 2007).
Stewart and colleagues (2004a) also found that some 
young strabismic children, not previously treated, improved 
visual acuity in the amblyopic eye only with refractive 
correction, even in the absence of anisometropia.
Occlusion
The traditional and most widely used method of amblyopia 
treatment is occlusion of the healthy eye, despite the lack of 
data demonstrating its superiority over other options. There 
is no accepted standard number of patching hours per day 
necessary to achieve a beneﬁ  cial effect.
PEDIG has investigated different patching modalities in 
amblyopia treatment. ATS 2A and ATS 2B were randomized 
clinical studies that compared different patching regimens 
treating severe and moderate amblyopia, respectively.
The ATS 2A compared 6 hours versus full-time daily 
patching combined with 1 hour of daily near activities while 
patching for severe amblyopia, in 175 children younger than 
7 years with severe amblyopia (20/100 to 20/400). The extra 
patching regimen did not appear to obtain added beneﬁ  t in 
the treatment. Younger children and children who began the 
study with worse visual acuity in their amblyopic eye, were 
shown to have a greater improvement in amblyopic eye acu-
ity (PEDIG 2003b).
The ATS 2B compared 2 versus 6 hours of daily patch-
ing combined with 1 hour of daily near activities while 
patching for the treatment of moderate amblyopia. It 
included 189 children younger than 7 years with moderate 
amblyopia (20/40 to 20/80). Once again, the extra patch-
ing did not give any added beneﬁ  t. The rapidity and course 
of improvement in the acuity of the amblyopic eye was 
identical in the two groups after four months of treatment 
(PEDIG 2003c).
In the prospective Monitored Occlusion Treatment of 
Amblyopia Study (MOTAS), children were prescribed 
6 hours of occlusion dose-monitored daily patching 
(Stewart et al 2004b). Mean visual acuity improved from 
0.50 ± 0.36 to 0.15 ± 0.25 logMAR. Average compliance 
was 48% of prescribed hours (2.8 hours). Increasing dosage 
beyond 2 hours a day did not affect the ﬁ  nal visual outcome, 
although they reached a successful outcome more quickly. 
The ﬁ  rst 6 weeks of treatment was the period when the 80% 
of the total improvement appeared. Visual outcome was 
better for younger children (4 years) than for older (6 
years). Dose-response was described as a linear function 
with a rate of 0.1 log unit (1 line) improvement per 120 
hours of occlusion.
Compliance issues with occlusion therapy
The success of amblyopia treatment must depend on com-
pliance with therapy, yet few studies have ever measured 
compliance objectively.
Occlusion dose monitors have conﬁ  rmed that not all 
children and parents comply well with patching. Parents and 
carers should be given information, convinced of the need 
for treatment, and appropriately motivated to treat (Searle 
et al 2002; Gregson 2002).
In the MOTAS study, occlusion episodes were recorded 
by an occlusion dose monitor (ODM) (Stewart et al 2004b). 
The ODM consisted of an eye patch with two small elec-
trodes attached to its undersurface that were connected to a 
battery-powered data logger. In this phase, both visual and 
monitored occlusion dose were recorded at 2-week intervals. 
At each visit, data from the OMD were downloaded to a 
computer, and parents were given the opportunity to review 
their child’s concordance.
Mean concordance with the prescribed occlusion dose rate 
(6h/d) was 2.8 hours (48%). Only 10 (14%) of participants 
achieved an average concordance within 30 minutes of the 
prescribed dose rate. Inter and intraparticipant variation 
was considerable. The ODM, although still too complex 
to implement for routine clinical use, seems to assess 
compliance reliably for research purposes. In another study, 
patient adherence to the prescribed patching regimen was 
considered excellent in 49%, poor in 5%, and intermediate 
in the remaining patients (PEDIG 2002).
Occlusion side effects
Classical adverse effects of occlusion treatment are local irri-
tation and allergy, impaired binocularity during treatment, and 
uncosmetic, and distressing effect (PEDIG 2002, 2003d).
Clinically signiﬁ  cant reverse amblyopia may be induced 
by excessive treatment with occlusion, but is typically of low Clinical Ophthalmology 2007:1(4) 408
de Zárate and Tejedor
incidence as a persistent effect (1%), and is usually transient 
and reversible when treatment is discontinued (Kutschke et al 
1991; Simons et al 1997; PEDIG 2002, 2005a).
PEDIG designed a questionnaire to asses the effect of 
amblyopia treatment on the child and parents (Amblyopia 
Treatment Index). This questionnaire was completed by the 
parent at the 5 week visit and measured the adverse effects 
of treatment, difﬁ  culties with compliance and social stigma 
of treatment. Adverse effects from patching were infrequent 
and mild (PEDIG 2003d).
In the ATS, although no deﬁ  nite cases of a persistent 
treatment-related decrease in the sound eye acuity occurred 
in either group (patching or penalization), more patients in 
the atropine group than the patching group had a measured 
reduction of visual acuity in the sound eye at the six month 
outcome examination (PEDIG 2002). Skin irritation occurred 
at least once at a moderate level in 41% and at a moderate or 
severe level in 6% of patients (PEDIG 2002).
In the ATS (which compared patching with atropine 
in moderate amblyopia) the Amblyopia Treatment Index 
questionnaire results indicated worse scores in all catego-
ries for patients enrolled in the patching group (PEDIG 
2003d).
In the ATS 2A, the Amblyopia Treatment Index showed 
similar scores between the 6-hour and full-time groups on 
all 3 subscales (adverse effects, treatment compliance, social 
stigma) (PEDIG 2003b).
In the ATS 2B the Amblyopia Treatment Index showed 
that the adverse effects and treatment compliance were 
similar in both groups (two hour versus 6 hour patching), 
but the social stigma of patching was worse in the 6-hour 
group (PEDIG 2003c).
The question about a possible better binocular outcome 
with atropine therapy than with occlusion has yet not been 
answered (Simons et al 1997). However, in ATS, there was 
no difference in outcome on several fusion and stereopsis 
measures between occlusion and penalization, or even a 
slightly better outcome in the occluded group for purely 
anisometropic patients (PEDIG 2005a).
Liquid crystal glasses
Liquid crystal glasses have recently been developed as a 
new treatment for amblyopia. Liquid crystal glasses with the 
appropriate correction provide an electronic, controlled, inter-
mittent occlusion of the sound eye allowing for visual stimuli 
input to the amblyopic fellow eye. A liquid crystal glass in the 
sound eye is used as an intermittent ﬂ  ickering shutter switched 
between “on”, or occlusion, and “off”, or light transmission. 
The ﬂ  ickering sequence can be adaptated to the depth of 
amblyopia, the length of treatment, and the patient’s age.
In a short evaluation of the new treatment, ten amblyopic 
children fulﬁ  lled the study. After 5 weeks wearing this type of 
glasses near mean visual acuity had been improved reaching 
statistical signiﬁ  cance. No control patients were included in 
the study (BenEzra et al 2007).
Opaque (occluder) contact lenses
Occluder contact lenses can be used in the treatment of 
amblyopia when children do not comply with patching. 
Children can improve therapy compliance using occlusive 
contact lenses. This treatment is ideal in patients who are 
patch-intolerant and fail with conventional treatment. These 
patients should have close follow-up in order to prevent 
anterior segment complications and amblyopia recurrence 
(Eustis and Chamberlain 1996).
Penalization
Classically, penalization has been used as a second treatment 
when occlusion was not complied with, or for post-occlusion 
as a maintenance treatment (France and France 1999). 
Recently, however, it has begun to be used as a primary 
treatment modality (PEDIG 2002). There are two main types 
of penalization: pharmacologic and optical penalization.
Pharmacologic penalization
As a way to treat amblyopia, atropine is instilled into the 
sound eye to prevent accommodation. It is thought to operate 
by blurring vision in the sound eye at near, thus forcing the 
amblyopic eye to be used preferentially for near vision tasks. 
When the sound eye is hypermetropic, the penalization effect 
can be potentiated by prescribing less than the full hyperopic 
correction for the sound eye, blurring its vision at both near 
and distance ﬁ  xation. Pharmacologic penalization has been 
usually advocated for mild or moderate amblyopia (20/100 
or better), because it is thought to be insufﬁ  cient when acuity 
in the amblyopic eye is worse than 20/100 (North and Kelly 
1987; Simons et al 1997).
In a PEDIG trial (ATS), patching for at least 6 hours per 
day was compared with a 1% atropine drop every morn-
ing in children aged 3–7 years with moderate amblyopia 
(PEDIG 2002). At 2 years of follow-up, mean improvements 
were similar in both groups. The researchers concluded 
that patching was initially faster and atropine had higher 
acceptability based on a parental questionnaire.
Since one dose of 1% atropine lasts up to 2 weeks, 
a less than daily dose might also be effective. PEDIG Clinical Ophthalmology 2007:1(4) 409
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compared daily atropine with twice weekly atropine in 
moderate amblyopia in children younger than 7 years. 
The improvement in visual acuity was the same in both 
groups, and the researchers concluded that twice a week 
atropine provides an improvement in visual acuity of similar 
magnitude as daily atropine (Morrison et al 2005).
Side effects of atropine
Like with other types of treatment, during atropine therapy, 
vision in the treated eye should be checked to ensure that 
no iatrogenic reverse amblyopia has taken place (Morrison 
et al 2005). During atropine treatment, this vision check-
ing could be difficult, since pupillary dilatation often 
results in a slight reduction of visual acuity even after full 
hypermetropic correction. In two PEDIG studies, only one 
of 372 patients treated with atropine was treated for reverse 
amblyopia, and only two patients lost more than one line 
from baseline in their healthy eye (PEDIG 2002, 2004a). In 
another study, no cases of reverse amblyopia were reported 
(Simons et al 1997).
Classically, it has been thought that fixation to the 
amblyopic eye was needed for treatment to be effective. 
This was the reason to consider atropine ineffective to treat 
severe amblyopia. PEDIG studies have demonstrated that 
ﬁ  xation switch is not needed for amblyopia recovery (PEDIG 
2003a, 2004a).
Optical penalization
Optical penalization for distance, adding plus correction 
to cycloplegic refraction in the sound eye (until ﬁ  xation at 
distance shifts to the amblyopic eye), is a useful alternative 
to occlusion for treating amblyopia, and as maintenance 
therapy following occlusion. It is particularly useful 
in cases of patching noncompliance. The major key to 
patient acceptance is choosing the minimal amount of 
penalization necessary, while still ensuring that the patient 
actually switches ﬁ  xation to the amblyopic eye (Repka 
et al 1985).
Optical penalization is an effective treatment for moderate 
amblyopia and can be choosed either as ﬁ  rst treatment 
choice or as an alternative after patching failure, as well as 
combined with other modalities of therapy (Simons et al 
1997; Kaye et al 2002).
Combined therapy
Combined optical and atropine penalization is an effective 
treatment when occlusion therapy fails initially, and it might 
have a more rapid effect than single modality penalization 
therapy, but incidence of reverse amblyopia could be 
higher (Kaye et al 2002; Morrison et al 2005). Its effect 
may be particularly useful in anisometropic amblyopia 
(Kaye et al 2002).
Penalizing ﬁ  lters
Ryser or Bangerter foils, which come in successive graduated 
densities, may be used to reduce visual acuity of the sound 
eye to less than the amblyopic eye, or to a poor level of visual 
acuity in all cases. Sometimes, adhesive tape or nail polish 
was used as a readily available procedure to produce fogging 
in the sound eye. These methods are used in mild amblyopia 
or as maintenance therapy, in school age cooperative children 
(France and France 1999).
Comparison between treatments
Classically, occlusion has been thought to be more effective 
than penalization in the treatment of amblyopia. But recently, 
based on some prospective clinical studies, atropine has 
become the ﬁ  rst step of amblyopia treatment in some cases 
(Foley-Nolan et al 1997; PEDIG 2002).
The ATS was a randomized, controlled, single-
masked, multicenter clinical trial designed to compare 
the improvement in visual acuity obtained with patching 
treatment versus pharmacologic penalization (PEDIG 2002). 
Occlusive therapy consisted of patching the sound eye for 
a minimum of 6 hours a day. Pharmacologic penalization 
of the sound eye consisted of dropping topical 1% atropine 
sulphate daily. Patients were children younger than 7 years 
with moderate amblyopia resulting from strabismus and or 
anisometropia. At baseline, the mean visual acuity in the 
amblyopic eye was 0.53 logMAR units (20/60). The mean 
interocular acuity difference was 4.4 lines.
The 6-month primary-outcome examination demon-
strated a mean improvement in visual acuity from baseline 
of 3.16 lines in the patching group and of 2.84 lines in 
atropine group. This difference in visual acuity was not 
statistically significant between the two groups. They 
found that patching was faster than atropine in recover-
ing amblyopia. The improvement in visual acuity did not 
depend on the cause of amblyopia, the baseline acuity, or 
the patient’s age. Children treated with patching more than 
10 hours per day had faster recovery. Adverse effects from 
patching or atropine use were infrequent and mild. Reverse 
amblyopia was rare.
In the Amblyopia Treatment Index questionnaire, there 
were more favorable scores in adverse effects, compliance, 
and social stigma for the atropine group.Clinical Ophthalmology 2007:1(4) 410
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The PEDIG continued the study from the six-month 
ﬁ  rst evaluation (PEDIG 2005a). In this second study, the 
participating investigators could prescribe any type of 
amblyopia therapy, or even no therapy. Most patients in 
both groups were prescribed amblyopia therapy (91% in 
the patching group and 85% in the atropine group). During 
the second year outcome examination, approximately one 
third of patients were still being treated for amblyopia. 
Regarding the modality of treatment in this second phase, 
patching was prescribed for 84% of children treated with 
patching during the initial 6 months, whereas atropine was 
prescribed for 78% of children previously treated with 
atropine. Switch to the opposite treatment ocurred in 28% 
of the patching group and 25% of the atropine group. Both 
treatments were prescribed, although not generally at the 
same time, for 21% in the patching group and 18% in the 
atropine group.
Additional improvement was observed in both treatment 
groups at 2 years. There continued to be no meaningful 
difference between groups in either mean visual acuity score 
or lines of improvement. At 2 years, only 50% of amblyopic 
eyes in both treatment eyes were 20/25 or better compared 
with 94% of sound eyes, and in both treatment groups the 
amblyopic eye was 1.8 lines worse than the sound eye. At 
2 years, approximately one third of patients in each group was 
still under treatment; the improvement with either patching 
or atropine happened even after 6 months of treatment. 
There was no difference in binocular vision between both 
groups. A subgroup analysis limited to the patients with 
anisometropic amblyopia suggested that binocular vision 
might be better in the patching group than in the atropine 
group, contradicting the classical hypothesis.
Pharmacological systemic therapy
Recently, levodopa and citicoline have appeared as a new 
potential modality of treatment for amblyopia, basically 
in combination with occlusion therapy. Levodopa is a 
pro-drug that acts at the central nervous system, where it 
is supposed to have a potential effect added to occlusion, 
and citicoline has essentially the same effect. Although 
some recent publications have shown beneﬁ  cial effect 
of this treatment in combination with occlusion therapy 
(Gottlob et al 1995; Leguire et al 2002; Pandey et al 2002; 
Bhartiya et al 2002), and that it might prolong the critical 
period during which occlusion is effective, its effect is 
thought to be temporary (Pandey et al 2002). Other studies 
have shown no beneﬁ  t of levodopa/carbidopa (Bhartiya 
et al 2002).
Near activities during amblyopia 
therapy
In PEDIG randomized trials of patching regimes for 
amblyopia, near visual activities were incorporated into 
each of the prescribed treatment regimens. Although these 
different treatments combined with near activities were 
successful in improving visual acuity in most children, it 
is unknown the effect of the near activities in the therapy 
of amblyopia.
PEDIG conducted a multicenter pilot study to determine 
if children randomized to near or non-near activities would 
perform prescribed activities, and to estimate the effect of 
near activities in visual acuity of the amblyopic eye combined 
with two hours of daily patching (PEDIG 2005c). Sixty-four 
children aged 3 to less than 7 years old, with strabismic and/or 
anisometropic amblyopia (20/40 to 20/400) were randomly 
assigned to receive either 2 hours of daily patching with near 
activities or 2 hours of daily patching without near activities. 
Children assigned to near visual activities performed more 
near activities than those assigned to non-near activities. 
After 4 weeks of treatment, there was a greater improvement 
in amblyopic eye visual acuity in those assigned to near 
visual activities. This difference was present only in the 
group of severe amblyopia. The improvement in amblyopic 
eye visual acuity was the same in the group of near visual 
activities than the group of non-near visual activities for 
moderate amblyopia.
Reverse amblyopia
Reverse amblyopia occurs when visual acuity decreases in 
the sound eye during amblyopia treatment.
Clinically, reverse amblyopia can come up from exces-
sive administration of treatment by patching or penaliza-
tion, but is not frequent and when it arises, it is generally 
transient and reversible. Treatment of suspected reverse 
amblyopia consists of checking refraction and vision, 
stopping active treatment, and ﬁ  nally treating the previ-
ously sound eye.
In the ATS, visual acuity in the sound eye at 6 month 
examination was decreased by 1 line in 7% of patients in 
the patching group and 15% in the atropine group. A two 
or more lines decrease was seen in 1% of the patching 
group and 9% of the atropine group. Only 1 patient (from 
atropine group) was actively treated for a presumed reverse 
amblyopia, with a return of visual acuity to its baseline level 
(PEDIG 2002).
Morrison and colleagues (2005) reported two cases of 
reverse amblyopia during treatment with atropine and optical Clinical Ophthalmology 2007:1(4) 411
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penalization. Both cases required active treatment to correct 
the reverse amblyopia. In one case visual acuity returned 
to normal and the second was lost to follow up. The author 
recommends frequent patient monitoring when using this 
combined therapy.
Recurrence of amblyopia 
after treatment
The factors affecting amblyopia recurrence are not clear. It 
has been suggested that poor initial visual acuity, strabismic 
amblyopia (Levartovsky et al 1995), and low age at the end 
of treatment (Levartovsky et al 1992) are risk factors for 
amblyopia recurrence after therapy cessation.
Recent studies suggest that approximately 20% to 25% 
of patients suffer amblyopia recurrence after successful 
treatment during the first year without therapy (Flynn 
et al 1999; PEDIG 2004b; Bhola et al 2006; Nilsson et al 
2007). The recurrence appears generally within the ﬁ  rst 
year after treatment ending, the majority of recurrences 
appearing within the ﬁ  rst 6 months (PEDIG 2004b; Nilsson 
et al 2007).
PEDIG found that the risk of recurrence was higher in 
those children who stopped treatment abruptly, than in those 
who reduced treatment before cessation. They did not ﬁ  nd 
any difference in recurrence rates between patients who had 
been on patching or on atropine therapy (PEDIG 2004b).
An inverse relationship between age at cessation of 
amblyopia treatment and risk of recurrence was found. The 
authors of the study concluded that there was a clinically 
important risk of amblyopia recurrence when occlusion 
therapy was decreased or stopped before the age of 10 years. 
They did not ﬁ  nd relationship between visual acuity of the 
amblyopic eye at the time of decrease or cessation of treatment 
and risk of recurrence (Bhola et al 2006). A very recent study 
indicates that strabismic amblyopia is a risk factor for recur-
rence despite maintenance therapy (Nilsson et al 2007).
In conclusion, before treatment cessation, therapy should 
be weaned in order to avoid recurrence. After treatment 
cessation, children should be followed for at least one year, 
with particular emphasis on the ﬁ  rst 6 months. Strabismic 
patients are especially at risk for recurrence.
Age-sensitive periods
It is generally believed that the “critical period” for visual 
development in humans ends at the age of 6 to 7 years (Von 
Noorden and Crawford 1979). Some eye care professionals 
believe that amblyopia treatment is successful in children 
up to 6 or 7 years while other think that this treatment can 
be effective until 9 or 10 years. The American Academy of 
Ophthalmology Preferred Practice Pattern for amblyopia rec-
ommends treatment up to age 10 years (American Academy 
of Ophthalmology 2002).
Mintz-Hittner and Fernandez (2000), reported signiﬁ  cant 
improvements in visual acuity in children aged 7 to 10.3 years 
treated with occlusion or penalization therapy. This study 
included 36 compliant children with strabismic or strabismic 
and anisometropic amblyopia. Initial visual acuities were 
between 20/50 and 20/400. Therapy consisted in occlusion 
(full-time standard occlusion or full-time occlusive contact 
lenses) or total penalization. Final visual acuities were 
between 20/20 and 20/30 for all patients.
In another study, sixteen nontreated amblyopes aged 
between 9 to 14.5 years began occlusion therapy (Park et al 
2004). The visual acuities ranged from 20/100 to 20/30. Full-
time occlusion was performed in 14 patients and part-time 
occlusion in two patients. The ﬁ  nal visual acuity improved 
in 94% of them at least two lines.
In the ATS, no effect of age was found at the 6-month 
primary outcome in children aged 3 to 7 years (PEDIG 2002). 
Only a very small effect was seen at the 2-year follow-up, 
with children aged 6–7 years having a slightly worse outcome 
than those aged less (PEDIG 2005a).
A PEDIG trial enrolled 7 to 17 year old patients with 
anisometropic and strabismic amblyopia ranging from 
6/12 to 6/120 (PEDIG 2005b). The patients were random-
ized to a treatment group (2–6 hours per day of prescribed 
patching combined with near visual activities for all patients 
plus atropine sulphate for children aged 7 to 12 years) 
or an optical correction group (optical correction alone). 
They were considered responders those whose amblyopic 
eye improved 10 or more letters. In the patients aged 7 to 
12 years old, 53% of the treatment group were responders 
compared with 25% of the optical correction group. In the 
patients aged 13 to 17 years, only 25% of the treatment 
group were responders compared with 23% in the optical 
correction group, but among patients not previously treated 
with patching and/or atropine for amblyopia, 47% of the 
treated responded compared with 20% of the responders in 
the optical correction group. They concluded that amblyopia 
in children aged 7–12 years should be treated with occlusion, 
near activities and atropine, even if amblyopia had been 
previously treated. In patients aged 13–17 years, amblyopia 
should be treated with occlusion and near activities; this 
treatment may improve visual acuity in case no previous 
treatment had been done. If patients had received previous 
therapy, a treatment response would be unlikely.Clinical Ophthalmology 2007:1(4) 412
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In MOTAS (Stewart et al 2004b), occlusion treatment 
outcome was better in children younger than 4 years than in 
those older than 6 years. This mean improvement in visual 
acuity (log units) increased signiﬁ  cantly with decreasing age 
(under 4 years, 0.43 ± 0.25; 4 to 6 years, 0.29 ± 0.19; over 
6 years, 0.19 ± 0.12). They provided further evidence that 
treatment age is a factor that inﬂ  uences the effectiveness of 
occlusion.
No difference in visual outcome between children 
receiving amblyopia treatment at the age of 3 or 5 years 
was found in a recent investigation (Clarke et al 2003). 
Deferring treatment did not affect the ﬁ  nal visual acuity, 
and even nearly halved the proportion of children requiring 
patching. They concluded that delay in treatment until the 
age of 5 years did not inﬂ  uence outcome.
Apparently, the critical period is not the same for 
different functions. The upper age limit for effective treat-
ment of amblyopia may be considered at 5 years, whereas 
risk for recurrence is still present up to 8–10 years. The 
critical period for amblyopia development lasts probably 
until 6–7 years.
References
Allen HF. 1957. A new picture series for preschool vision testing. Am J 
Ophthalmol, 44:38–41.
American Academy of Ophthalmology. 2002. Preferred Practice 
Pattern: Amblyopia. San Francisco, Calif: American Academy of 
Ophthalmology.
Atilla H, Oral D, Coskun S, et al. 2001. Poor correlation between “ﬁ  x-follow-
maintain” monocular/binocular ﬁ  xation pattern evaluation and presence 
of functional amblyopia. Binocul Vis Strabismus Q, 16:85–90.
Atkinson J, Braddick O. 1983. Assesment of visual acuity in infancy and 
early childhood. Acta Ophthalmol Scand Suppl, 18–26.
Beck RW, Moke PS, Turpin AH, et al. 2003. A computerized method of 
visual acuity testing: adaptation of the early treatment of diabetic reti-
nopathy study testing protocol. Am J Ophthalmol, 135:194–205.
Becker R, Hübsch S, Gräf MH, et al. 2002. Examination of young children 
with Lea symbols. Br J Ophthalmol, 86:513–16.
Becker R, Gräf M. 2006. Landolt C and Snellen e acuity: differences in 
strabismus amblyopia? Klin Monatsbl Augenheilkd, 223:24–8.
BenEzra O, Herzog R, Cohen E, et al. 2007. Liquid crystal glasses: fea-
sibility and safety of a new modality for treating amblyopia. Arch 
Ophthalmol, 125:580–1.
Bhartiya P, Sharma P, Biswas NR. 2002. Levodopa- carbidopa with occlu-
sion in older children with amblyopia. J AAPOS, 6:368–72.
Bhola R, Keech RV, Kutschke P, et al. 2006. Recurrence of amblyopia after 
occlusion therapy. Ophthalmology, 113:2097–100.
Browder JA, Levy WJ. 1974. Vision testing of young and retarded children. 
Experience with the British STYCAR screening test. Clin Pediatr, 
13:983–6.
Chen PL, Chen JT, Tai MC, et al. 2007. Anisometropic amblyopia treated 
with spectacle correction alone: possible factors predicting success and 
time to start patching. Am J Ophthalmol, 143:54–60.
Chua B, Mitchell P. 2004. Consequences of amblyopia on education, occupa-
tion and long term vision loss. Br J Ophthalmol, 88:1119–21.
Clarke MP, Wright CM, Hrisos S, et al. 2003. Randomised controlled trial 
of treatment of unilateral visual impairment detected at preschool vision 
screening. BMJ, 327:1251–6.
Cleary M. 2000. Efﬁ  cacy of occlusion for strabismic amblyopia: can an 
optimal duration be identiﬁ  ed? Br J Ophthalmol, 84:572–7.
Cotter SA, Edwars AR, Wallace DK, et al. 2006. Treatment of anisometropic 
amblyopia in children with refractive correction. Ophthalmology, 
113:895–903.
Cotter SA, Edwars AR, Arnold RW, et al. 2007. Treatment of strabismic 
amblyopia with refractive correction. Am J Ophthalmol, 143:1060–3.
Eustis HS, Chamberlain D. 1996. Treatment for amblyopia: results using 
occlusive contact lens. J Pediatr Ophthalmol Strabismus, 33:319–22.
Ferris III FL, Kassof A, Bresnick GH, et al. 1982. New visual acuity charts 
for clinical research. Am J Ophthalmol, 94:91–6.
Flynn JT, Woodruff G, Thompson JR, et al. 1999. The therapy of amblyopia: 
an analysis comparing the results of amblyopia therapy utilizing two 
pooled data sets. Trans Am Ophthalmol Soc, 97:373–90.
Foley-Nolan A, McCann A, O’Keefe M. 1997. Atropine penalisation versus 
occlusion as the primary treatment for amblyopia. Br J Ophthalmol, 
81:54–7.
France TD, France LW. 1999. Optical penalization can improve vision after 
occlusion treatment. J AAPOS, 3:341–3.
Getz LM, Dobson V, Luna B, et al. 1996. Interobserver reliability of the 
Teller Acuity Card procedure in pediatric patients. Invest Ophthalmol 
Vis Sci, 37:180–7.
Gottlob I, Wizov SS, Reinecke RD. 1995. Visual acuities and scotomas 
after 3 weeks’ levodopa administration in adult amblyopia. Graefes 
Arch Clin Exp Ophthalmol, 233:407–13.
Gräf M, Becker R, Kaufmann H. 2000. Lea symbols: visual acuity 
assessment and detection of amblyopia. Graefes Arch Clin Exp 
Ophthalmol, 238:53–8.
Gregson R. 2002. Why are we so bad at treating amblyopia? Eye, 
16:461–2.
Grimm W, Rassow B, Wesemann W, et al. 1994. Correlation of optotypes 
with the Landolt ring, a fresh look at the comparability of optotypes. 
Optom Vis Sci, 71:6–13.
Harvey EM, Dobson V, Tung B, et al. 1999. Interobserver agreement 
for grating acuity and letter acuity assessment in 1-to 5.5-years-old 
with severe retinopathy of prematurity. Invest Ophthalmol Vis Sci, 
40:1565–76.
Hazell CD. 1995. Evaluation of the Cardiff acuity test in uniocular 
amblyopia. Br Orthopt J, 52:8–15.
Hered RW, Murphy S, Clancy M. 1997. Comparison of the HOTV and Lea 
Symbols charts for preschool vision screening. J Pediatr Ophthalmol 
Strabismus, 34:24–8.
Hillis A, Flynn JT, Hawkins BS. 1983. The evolving concept of amblyopia 
a challenge to epidemiologists. Am J Epidemiol, 118:192–205.
Holmes JM, Beck RW, Repka MX, et al. 2001. The amblyopia treat-
ment study visual acuity testing protocol. Arch Ophthalmol, 
119:1345–53.
Hubel DH, Wiesel TN. 1970. The period of susceptibility to the 
physiological effects of unilateral eye closure in Kittens. J Physiol, 
206:419–36.
Hyvarinen L, Nasanen R, Laurinen P. 1980. New visual acuity test for pre-
school children. Acta Ophthalmologica, 58:507–11.
Kay H. 1983. New method of assessing visual acuity with pictures. Br J 
Ophthalmol, 67:131–3.
Kaye SB, Chen SI, Price G, et al. 2002. Combined optical and atropine 
penalization for the treatment of strabismic and anisometropic 
amblyopia. J AAPOS, 6:289–93.
Klimek DL, Cruz OA, Scott WE, et al. 2004. Isoametropic amblyopia due 
to high hyperopia in children. J AAPOS, 8:310–13.
König HH, Barry JC. 2004. Cost effectiveness of treatment for amblyopia: 
an analysis based on a probabilistic Markov model. Br J Ophthalmol, 
88:606–12.
Kutschke PJ, Scott WE, Keech RV. 1991. Anisometropic amblyopia. 
Ophthalmology, 98:258–63.
Kvarnström G, Jakobsson P, Lennerstrand G. 2001. Visual screening of 
Swedish children: an ophthalmological evaluation. Acta Ophthalmol 
Scand, 79:240–4.Clinical Ophthalmology 2007:1(4) 413
Treatment of amblyopia
Lam GC, Repka MX, Guyton DL. 1993. Timing of amblyopia therapy rela-
tive to strabismus surgery. Ophthalmology, 100:1751–6.
Leguire LE, Komaromy KL, Nairus TM, et al. 2002. Long-term follow-up 
of L-dopa treatment in children with amblyopia. J Pediatr Ophthalmol 
Strabismus, 39:326–30.
Levartovsky S, Gottesman N, Shimshoni M, et al. 1992. Factors affecting 
long-term results of successfully treated amblyopia: age at beginning 
of treatment and age at cessation of monitoring. J Pediatr Ophthalmol 
Strabismus, 29:219–23.
Levartovsky S, Oliver M, Gottesman N, et al. 1995. Factors affecting long 
term results of successfully treated amblyopia: initial visual acuity and 
type of amblyopia. Br J Ophthalmol, 79:225–8.
Mayer DL, Fulton AB, Rodier D. 1984. Grating and recognition acuities of 
pediatric patients. Ophthalmology, 91:947–53.
McGraw PV, Winn B. 1993. Glasgow acuity cards: a new test for the 
measurement of letter acuity in children. Ophthalmic Physiol Opt, 
13:400–4.
McGraw PV, Winn B, Gray LS, et al. 2000. Improving the reliability of 
visual acuity measures in young children. Ophthalmic Physiol Opt, 
20:173–84.
Membreno JH, Brown MM, Brown GC, et al. 2002. A cost-utility analysis 
of therapy for amblyopia. Ophthalmology, 109:2265–71.
Mintz–Hittner H, Fernandez K. 2000. Succesful amblyopia therapy 
initiated after age 7 years: compliance cures. Arch Ophthalmol, 
118:1535–41.
Moke PS, Turpin AH, Beck RW, et al. 2001. Computerized method of visual 
acuity testing: adaptation of the amblyopia treatment study visual acuity 
testing protocol. Am J Ophthalmol, 132:903–9.
Morad Y, Werker E, Nemet P, et al. 1999. Visual acuity tests using chart, 
line, and single optotype in healthy and amblyopic children. J AAPOS, 
3:94–7.
Morrison DG, Palmer NJ, Sinatra RB, et al. 2005. Severe amblyopia of 
the sound eye resulting from atropine therapy combined with optical 
penalization. J Pediatric Ophthalmol Strabismus, 42:52–3.
Moseley MJ, Neufeld M, Fielder AR. 1998. Treatment of amblyopia by 
spectacles. Invest Ophthalmol Vis Sci, 39:S332.
Moseley MJ, Neufeld M, McCarry B, et al. 2002. Remediation of refractive 
amblyopia by optical correction alone. Ophthalmic Physiol Opt, 
22:296–9.
Nilsson J, Baumann M, Sjöstrand J. 2007. Strabismus might be a risk factor 
for amblyopia recurrence. J AAPOS, 11:240–2.
North RV, Kelly ME. 1987. A review of the uses and adverse effects of topi-
cal administration of atropine. Ophthalmol Physiol Opt, 7:109–14.
Oster JG, Simon JW, Jenkins P. 1990. When is it safe to stop patching? 
Br J Ophthalmol, 74:709–11.
Pandey PK, Chaudhuri Z, Kumar M. 2002. Effect of levodopa and carbidopa 
in human amblyopia. J Pediatr Ophthamol Strabismus, 39:81–9.
Park KH, Hwang J-M, Ahn JK. 2004. Efﬁ  cacy of amblyopia therapy initi-
ated after 9 years of age. Eye, 18:571–4.
Paysse EA, Coats DK, Hussein MA, et al. 2006. Long term outcomes of 
photorefractive Keratectomy for anisometropic amblyopia in children. 
Ophthalmology, 113:169–76.
[PEDIG] Pediatric Eye Disease Investigator Group. 2002. A randomized 
trial of atropine vs patching for treatment of moderate amblyopia in 
children. Arch Opthalmol, 120:268–78.
[PEDIG] Pediatric Eye Disease Investigator Group. 2003a. The course of 
moderate amblyopia treated with atropine in children: experience of the 
amblyopia treatment study. Am J Ophthalmol, 136:630–9.
[PEDIG] Pediatric Eye Disease Investigator Group. 2003b. A randomized 
trial of prescribed patching regimens for treatment of severe amblyopia 
in children. Ophthalmology, 110:2075–87.
[PEDIG] Pediatric Eye Disease Investigator Group. 2003c. A randomized 
trial of patching regimens for treatment of moderate amblyopia in 
children. Arch Ophthalmol, 121:603–11.
[PEDIG] Pediatric Eye Disease Investigator Group. 2003d. Impact of patch-
ing and atropine treatment on the child and family in the Amblyopia 
Treatment Study. Arch Ophthalmol, 121:1625–32.
[PEDIG] Pediatric Eye Disease Investigator Group. 2004a. A randomized 
trial of atropine regimens for treatment of moderate amblyopia in 
children. Ophthamology, 111:2076–85.
[PEDIG] Pediatric Eye Disease Investigator Group. 2004b. Risk of amblyo-
pia recurrence after cessation of treatment. J AAPOS, 8:420–8.
[PEDIG] Pediatric Eye Disease Investigator Group. 2005a. Two-year 
follow up of a 6-month randomized trial of atropine vs patching 
for treatment of moderate amblyopia in children. Arch Ophthalmol, 
123:149–57.
[PEDIG] Pediatric Eye Disease Investigator Group. 2005b. Randomized 
trial of treatment of amblyopia in children aged 7 to 17 years. Arch 
Ophthalmol, 123:437–47.
[PEDIG] Pediatric Eye Disease Investigator Group. 2005c. A randomized 
pilot study of near activities versus non-near activities during patching 
therapy for amblyopia. J AAPOS, 9:129–36.
Rahi J, Logan S, Timms C, et al. 2002. Risk, causes, and outcomes of visual 
impairment after loss of vision in the non-amblyopic eye: a population-
based study. Lancet, 360:597–602.
Rassow B, Wang Y. 1999. Correlation of letter optotypes with Landolt 
ring for different degrees of visual acuity. Klin Monatsbl Augenheilkd, 
215:119–26.
Repka MX, Gallin PF, Scholz RT, et al. 1985. Determination of opti-
cal penalization by vectographic ﬁ  xation reversal. Ophthalmology, 
92:1584–6.
Rydberg A, Ericson B. 1998. Assessing visual function in children younger 
than 1½ years with normal and subnormal vision: evaluation of methods. 
J Pediatr Ophthalmol Strabismus, 35:312–19.
Ruttum MS, Dahlgren M. 2006. Comparison of HOTV and Lea symbols 
visual acuity tests in patients with amblyopia. J Pediatr Ophthalmol 
Strabismus, 43:157–60.
Rydberg A, Ericson B, Lennerstrand G, et al. 1999. Assesment of visual 
acuity in children aged 1½-6 years, with normal and subnormal vision. 
Strabismus, 7:1–24.
Searle A, Norman P, Harrad R, et al. 2002. Psychosocial and clinical 
determinants of compliance with occlusion therapy for amblyopic 
children. Eye, 16:150–5.
Simons K, Stein L, Sener EC, et al. 1997a. Full-time atropine, intermittent 
atropine, and optical penalization and binocular outcome in treatment 
of strabismic amblyopia. Ophthalmology, 104:2143–55.
Simons K, Gotzler KC, Vitale S. 1997b. Penalization vs part-time occlu-
sion and binocular outcome in treatment of strabismic amblyopia. 
Ophthalmology, 104:2156–60.
Simons K, Preslan M. 1999. Natural history of amblyopia untreated owing 
to lack of compliance. Br J Ophthalmol, 83:582–7.
Snowdon SK, Stewart-Brown SL. 1997. Preschool vision screening. Health 
Technol Assess, 1:1–83.
Stewart CE, Moseley MJ, Fielder AR, et al. MOTAS Cooperative. 2004a. 
Refractive adaptation in amblyopia: quantification of effect and 
implications for practice. Br J Ophthalmol, 88:1552–6.
Stewart CE, Moseley MJ, Stephens DA, et al. 2004b. Treatment 
Dose-Response in Amblyopia Therapy: The Monitored Occlusion 
Treatment Of Amblyopia Study (MOTAS). Invest Ophthalmol Vis 
Sci, 45:3048–54.
Tommila V, Tarkkanen A. 1981. Incidence of loss of vision in the healthy 
eye in amblyopia. Br J Ophthalmol, 65:575–7.
Tychsen L, Packwood E, Berdy G. 2005. Correction of large amblyo-
piogenic refractive errors in children using excimer laser. J AAPOS, 
9:224–33.
Van Leeuwen R, Eijkemans MJ, Vingerling JR, et al. 2007. Risk of bilateral 
visual impairment in persons with amblyopia: The Rotterdam Study. 
Br J Ophthalmol, doi:10.1136/bjo.2006.113670.
Von Noorden GK, Crawford ML. 1979. The sensitive period. Trans 
Ophthalmol Soc UK, 99:442–6.
Von Noorden GK. 1996. Binocular Vision and Ocular Motility. St Lous: 
Mosby.
Wallace D. 2005. Tests of ﬁ  xation preference for amblyopia. Am Orthopt J, 
55:76–81.Clinical Ophthalmology 2007:1(4) 414
de Zárate and Tejedor
Weakley Jr DR. 2001. The association between nonstrabismic aniso-
metropia, amblyopia, and subnormal binocularity. Ophthalmology, 
108:163–71.
Woodhouse JM, Morjaria SA, Adler PM. 2007. Acuity measurements 
adult subjects using a preferential looking test. Ophthalmic Physiol 
Opt, 27:54–9.
Wright KW, Edelman PM, Walonker F, et al. 1986. Reliability of ﬁ  xa-
tion preference testing in diagnosing amblyopia. Arch Ophthalmol, 
104:549–53.